Overexpression of SCC-S2 correlates with lymph node metastasis and poor prognosis in patients with non-small-cell lung cancer

Cancer Science

Volumn 101, Issue 6, 2010, Pages 1562-1569

  Dong, Qian Ze ^a   Zhao, Yue ^a   Liu, Yang ^a   Wang, Yang ^a   Zhang, Peng Xin ^a   Jiang, Gui Yang ^a   Dong, Xin Jun ^a   Cui, Quan Ze ^a   Wang, En Hua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN SCC S2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; PROTEINS; RNA, MESSENGER;

EID: 77954172825     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01557.x     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E. Cancer statistics, 2007. CA Cancer J Clin 2007, 57(1):43-66.
2. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell 2002, 1(1):49-52.
3. Schiller JH, Harrington D, Belani CP. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(2):92-8.
4. Chen HY, Yu SL, Chen CH. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007, 356(1):11-20.
5. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64(2):327-36.
6. O'Mahony D, Kummar S, Gutierrez ME. Non-small-cell lung cancer vaccine therapy: a concise review. J Clin Oncol 2005, 23(35):9022-8.
7. Patel S, Wang FH, Whiteside TL. Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous cell carcinoma cell lines: implications in metastasis and/or radiation response. Oral Oncol 1997, 33(3):197-203.
8. Kumar D, Whiteside TL, Kasid U. Identification of a novel tumor necrosis factor-alpha-inducible gene, SCC-S2, containing the consensus sequence of a death effector domain of fas-associated death domain-like interleukin- 1beta-converting enzyme-inhibitory protein. J Biol Chem 2000, 275(4):2973-8.
9. Horrevoets AJ, Fontijn RD, van Zonneveld AJ. Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes. Blood 1999, 93(10):3418-31.
10. You Z, Ouyang H, Lopatin D. Nuclear factor-kappa B-inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity. J Biol Chem 2001, 276(28):26398-404.
11. Kumar D, Gokhale P, Broustas C. Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB 435 cells. Oncogene 2004, 23(2):612-6.
12. Zhang C, Chakravarty D, Sakabe I. Role of SCC-S2 in experimental metastasis and modulation of VEGFR-2, MMP-1, and MMP-9 expression. Mol Ther 2006, 13(5):947-55.
13. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9(6):669-76.
14. Shalaby F, Rossant J, Yamaguchi TP. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376(6535):62-6.
15. Veikkola T, Karkkainen M, Claesson-Welsh L. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000, 60(2):203-12.
16. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004, 16(5):558-64.
17. Rydlova M, Holubec L, Ludvikova M. Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res 2008, 28(2B):1389-97.
18. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516.
19. Davidson B, Konstantinovsky S, Nielsen S. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin Cancer Res 2004, 10(21):7335-46.
20. Rolli M, Fransvea E, Pilch J. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100(16):9482-7.
21. Tutton MG, George ML, Eccles SA. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer 2003, 107(4):541-50.
22. Takeuchi T, Hisanaga M, Nagao M. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res 2004, 10(16):5572-9.
23. Rollin J, Regina S, Vourc'h P. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 2007, 56(2):273-80.
24. Laack E, Scheffler A, Burkholder I. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer 2005, 50(1):51-8.